Tag: medical

Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series

SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) — Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.            About Retrophin Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s

Inc. Magazine Names PTS Diagnostics to its 2016 List of the 5,000 Fastest Growing Private Companies

INDIANAPOLIS, Sept. 14, 2016 (GLOBE NEWSWIRE) — PTS Diagnostics, the US-based manufacturer of point-of-care biometric testing devices distributed across the globe, has been selected for an impressive sixth time to the prestigious Inc. 5000 list. For the 2016 Inc. 5000 list, PTS Diagnostics placed as the 3,772nd fastest growing private company in America based on three-year revenue growth of 81%. PTS Diagnostics is one of only 237 of the 5,000 companies listed this year to have been chosen for four consecutive years.  This designation puts PTS Diagnostics in the top 50 fastest growing companies in Indiana. Founded in 1992, PTS

SR Scales Selected by Life Care Centers of America as Preferred Provider of Portable Wheelchair Scales

TONAWANDA, N.Y., Sept. 14, 2016 (GLOBE NEWSWIRE) — SR Instruments, a leading manufacturer of purpose-built scales for hospitals, medical facilities, and long term centers, today announced that its flagship product line, SR Scales, has been selected as the preferred provider of portable wheelchair scales for all Life Care Centers of America institutions. With over 200 locations nationwide, Life Care Centers provide unparalleled medical and rehabilitative care for their residents. “We needed to find an alternative approach to weighing our patients that would provide greater accuracy, repeatability, and ease of use for our staff,” said John Kitterman, Director of Purchasing at

Frontier Pharma: Chronic, Acute and Neuropathic Pain – GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes: ResearchMoz

Albany,NY, Sept. 14, 2016 (GLOBE NEWSWIRE) — Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain as a disease, rather than just as a symptom of a primary cause. In the US, pain affects more people than cancer, diabetes and heart disease combined, with an estimated 100 million people having experienced at least one chronic pain episode in the last 12 months, at an annual cost of around $600 billion in medical treatment and lost

Miramar Labs’ miraSmooth Procedure Featured on The Rachael Ray Show

SANTA CLARA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that its miraSmooth™ treatment was featured in the September 6th episode of “The Rachael Ray Show”, an award-winning and nationally syndicated daytime TV show. The theme of the episode, “Can 3 High-Tech Beauty Treatments Improve Your Problem Areas – Forever?” featured Dr. Whitney Bowe, a New York based board certified dermatologist, highlighting the miraDry/miraSmooth procedure. Dr. Bowe spoke about the benefits of miraSmooth’s microwave technology, including the permanent reduction of underarm sweat and hair of all color. The complete segment featuring

Carpenter Technology Announces Retirement Plan Changes

Will freeze General Retirement Plan effective December 31, 2016 Aligns retirement benefit plans for most employees WYOMISSING, Pa., Sept. 14, 2016 (GLOBE NEWSWIRE) — Carpenter Technology Corporation (NYSE:CRS) (the “Company”) today announced changes to retirement plans it offers to certain employees. The Company will freeze benefits accrued to eligible participants of the General Retirement Plan (“GRP”) effective December 31, 2016. The GRP is a defined benefit pension plan that currently includes approximately 1,900 domestic current salaried and hourly employees. The affected employees will be transitioned to the Company’s 401(k) plan that has been in effect for eligible employees since 2012,

Hurco Companies, Inc. Announces Quarterly Cash Dividend

INDIANAPOLIS, Sept. 14, 2016 (GLOBE NEWSWIRE) — Hurco Companies, Inc. (Nasdaq:HURC), an international industrial technology company, announced today that its Board of Directors approved the payment of a cash dividend of $0.09 per share.  The dividend will be paid on October 17, 2016, to shareholders of record as of the close of business on September 30, 2016.  Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change. About the Company Hurco Companies, Inc. is an international, industrial technology, company that sells its three brands of computer

Iris Plans Receives Venture Backing From Bay Area’s Better Ventures

AUSTIN, Texas, Sept. 14, 2016 (GLOBE NEWSWIRE) — Iris Plans, a tech-enabled Advance Care Planning (ACP) service for people facing serious medical conditions, announced today that Better Ventures has joined the company’s seed financing round. Iris Plans has now raised its original target of $750,000 for this round and will likely increase the size of the round due to additional investor interest. Iris Plans reduces the burden that serious medical conditions place on patients, families and the healthcare system, by providing ACP services through a telehealth platform. Iris Plans healthcare professionals meet with patients and their families anytime, anywhere, creating

INC Research and CISCRP Announce Finalists for “Inspiring Hope” Ideathon

RALEIGH, N.C., Sept. 14, 2016 (GLOBE NEWSWIRE) — INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, together with the Center for Information and Study on Clinical Research Participation (CISCRP), a non-profit organization dedicated to engaging the public and patients as partners in the clinical research process, today announced the finalists for the “Inspiring Hope” Ideathon event. In a competition that inspired nearly 70 entries, 14 ideas submitted by teams from around the world have been shortlisted for their potential to help address the critical need to increase awareness of clinical trial participation among

BioXcel’s BXCL101, Receives Orphan Drug Designation from the U.S. FDA for the Treatment of Patients with Neurofibromatosis Type 2 (NF2)

BRANFORD, Conn., Sept. 13, 2016 (GLOBE NEWSWIRE) — BioXcel, a privately held biopharmaceutical company based in Connecticut, today announced that the U. S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BXCL101 for the treatment of Neurofibromatosis Type 2 (NF2), an orphan disease with significant unmet medical need.  BXCL101 is the first and only systemic therapy being developed to eliminate existing lesions and prevent the formation of new lesions by targeting the molecular mechanism of NF2 pathophysiology. BXCL101 is a proprietary version of an approved drug, bortezomib, adapted for chronic use in NF2 patients with both a

Firsthand Technology Value Fund Discloses Top Portfolio Holdings

SAN JOSE, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (NASDAQ:SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, disclosed today that its top five holdings as of August 31, 2016 were IntraOp Medical, Pivotal Systems, QMAT, Wrightspeed, and Turn. IntraOp Medical Corp. is the manufacturer of the Mobetron, a medical device that is used to deliver intra-operative radiation to cancer patients. As of August 31, 2016, the Fund’s investment in IntraOp consisted of 26,856,187 shares of preferred stock plus debt securities and represented approximately 16.1% of the Fund’s

EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense

WALTHAM, Mass., Sept. 13, 2016 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Jade Therapeutics, Inc. (“Jade”), a wholly owned subsidiary of EyeGate, has received the second year of funding of $448,185 from the U.S. Army Medical Research and Materiel Command (USAMRMC) to continue the development of its proprietary thiolated hyaluronic acid (CMHA-S) for use as an ocular bandage film entitled “Novel Hyaluronic Acid Delivery Polymer for Repair of Ocular Injuries”. The second year of

ENT and Allergy Associates, LLP(R) Port Jefferson/East Patchogue, NY Practitioner Recognized for her Outstanding Contributions to the Field of Otolaryngology

TARRYTOWN, N.Y., Sept. 13, 2016 (GLOBE NEWSWIRE) — The ear, nose and throat specialists and sub-specialists of ENT and Allergy Associates (ENTA)-the nation’s preeminent otolaryngology practice-have long valued support offered to clinicians by the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS). Year after year, so many of the Practice’s 180+ physicians attend the AAO-HNS annual meeting, this year to be held September 18-21 in San Diego, California.  Indeed, dozens of ENTA physicians have spoken and led seminars at AAO-HNS events held during the convention. This year is particularly special to ENTA, because one of its own-Dr. Lauren

Feature Box

Vascular Solutions Surpasses 150,000 Successfully Reprocessed ClosureFAST® Catheters

Reprocessing service for varicose vein ablation catheter continues to gain customers nearly five years after launch Excellent record of safety and reliability Reprocessing lowers costs and reduces medical waste for U.S. vein clinics MINNEAPOLIS, Sept. 13, 2016 (GLOBE NEWSWIRE) — Vascular Solutions, Inc. (Nasdaq:VASC) today announced that more than 150,000 ClosureFAST catheters have been successfully reprocessed by its partner, Northeast Scientific, Inc. (NES), since Vascular Solutions launched the reprocessing service for the popular vein ablation catheters in January of 2012. “As we approach the fifth anniversary of the launch of our novel reprocessing service for the ClosureFAST catheter, we are

Organovo and Collaborators Publish Data in Toxicological Sciences Demonstrating Power of 3D Bioprinted Human Liver Tissues in Modeling Drug-Induced Liver Injury Leading to Fibrosis

SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced a publication in the scientific journal, Toxicological Sciences, which demonstrates the power of Organovo’s ExViveTM Human Liver Tissue to effectively model drug-induced liver injury leading to fibrosis. Using Organovo’s 3D bioprinted human liver tissues, researchers from Organovo, The Institute for Drug Safety Sciences and the University of North Carolina at Chapel Hill were able to reconstruct key aspects of methotrexate and thioacetamide-induced progressive human liver injury in a way

WellStar Health System expands Best Upon Request concierge service to six additional hospitals

MARIETTA, GA., Sept. 13, 2016 (GLOBE NEWSWIRE) — It has been a big year for WellStar Health System. The organization has partnered with West Georgia Medical Center of LaGrange, Georgia, in addition to acquiring five Tenet Healthcare Corporation hospitals. Joining them in this expansion is Cincinnati-based Best Upon Request Corporate, Inc. (BEST). BEST, an on-site concierge service provider, is offered to WellStar team members as a benefit to demonstrate how much they are valued by their employer. BEST first partnered with WellStar in 2009 to serve employees at Kennestone and Cobb Hospitals. In late 2015, the concierge program expanded to

Arbutus’ Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Sept. 13, 2016 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, has been awarded the 2016 Lasker~DeBakey Clinical Medical Research Award for the development of a revolutionary treatment of hepatitis C virus (HCV). Dr. Sofia now leads a world class team of scientists at Arbutus that is focused on developing innovative therapies to improve cure rates in HBV. “It is a tremendous honor to receive the Lasker~DeBakey Award for Clinical Medical Research, in recognition of

Feature Box

Miramar Labs’ CEO Interviewed on Bloomberg Radio

SANTA CLARA, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) — Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today that the company’s CEO, Mike Kleine, was interviewed on Bloomberg Radio’s “Taking Stock” on September, 12th, 2016 at 3:15pm EDT. In the interview, Mr. Kleine discussed the commercial momentum of the miraDry procedure and the significant market opportunity for the Company. The interview can be viewed at http://www.bloomberg.com/news/audio/2016-09-12/miramar-labs-wipes-away-sweat-glands-and-odor-audio “This interview with Bloomberg further demonstrates there is a growing interest in our company and the miraDry procedure. This is only one of the several steps we are taking to raise awareness and

Farmer Bros. Co. Reports Fourth Quarter and Fiscal 2016 Financial Results

FORT WORTH, Texas, Sept. 12, 2016 (GLOBE NEWSWIRE) — Farmer Bros. Co. (NASDAQ:FARM) (the “Company”) today reported financial results for its fourth quarter and fiscal year ended June 30, 2016. Fourth Quarter Fiscal 2016 Highlights: Net sales increased $1.6 million to $134.2 million in the fourth quarter of fiscal 2016, as compared to the prior year period; Gross profit increased 6.6% to $52.4 million in the fourth quarter of fiscal 2016, as compared to the prior year period; Net income was $84.2 million in the fourth quarter of fiscal 2016, primarily due to non-cash income tax benefit of $80.3 million from

AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2016

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended June 30, 2016. “Over the past year we’ve continued to make progress across our clinical programs and have remained focused on advancing novel gene-based therapies to improve the lives of patients affected by rare inherited diseases,” said Sue Washer, President and CEO of AGTC. “We are continuing to advance our lead product candidates for X-linked retinoschisis and